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Summary Successful generation of adherent lymphokine-activated killer (A-LAK) cells, highly-enriched in
CD3-CD56+ antitumour effector cells, from the peripheral blood of ten patients with acute myelogenous
leukaemia (AML) is described. The AML patients were either untreated or in remission. In vitro proliferation
of A-LAK cells in patients with AML was generally poor, unless the cells were cocultured with irradiated
concanavalin A (ConA) - prestimulated allogeneic PBL or selected lymphoblastoid cell lines (LCL) as feeder
cells. Using this method, the median fold proliferation was 290 for A-LAK cells cultured with ConA-activated
feeders and 291 for those grown with LCL, both significantly higher (both P<0.001) than the median of
2-fold expansion observed in cultures without feeders. A-LAK cultures generated in the presence of feeders
consistently showed good enrichment (up to 90%) in CD3-CD56+ NK cells. Although NK activity was not
significantly increased on a per cell basis in A-LAK cells grown with feeder cells, total lytic activities against
both NK-sensitive target, K562, and NK-resistant target, Daudi, were significantly greater (P<0.02 for
ConA-PBL feeders and P<0.005 for LCL feeders) as compared to those in paired cultures without feeders. In
the presence of irradiated allogeneic feeder cells, 7/10 AML patients generated A-LAK cultures characterised
by good proliferation and increased purity as well as cytotoxic activity.
In adoptive immunotherapy (AIT), tumouricidal cells derived
from the peripheral blood of peritumoural tissue in vitro
activation in the presence of recombinant interleukin-2 (IL-
2), are transferred back to a cancer patient (Grimm et al.,
1982; Itoh et al., 1986; Rosenberg et al., 1985; Rosenberg et
al., 1987). In vivo antimetastatic effects of such lymphokine-
activated killer (LAK) cells have been confirmed in animal
models of established tumour metastases (Lafreniere & Ros-
enberg, 1985; Mule et al., 1984). In clinical studies with
cancer patients, between 20 and 30% of patients with metas-
tatic renal cell carcinoma or melanoma, who were previously
unresponsive to conventional therapy, responded to AIT with
LAK cells (Rosenberg et al., 1985; Rosenberg et al., 1987). It
has been suggested that AIT might also be useful as a
possible treatment for leukaemia (Adler et al., 1988; Adler et
al., 1989). In contrast to solid tumours, where localisation of
adoptively-transferred cells to the tumour may play a crucial
role in success or failure of AIT, leukaemic blasts should be
more accessible to systemically-administered effector cells. A
feasible approach could be to collect and cryopreserve PBL
from patients with leukaemia in remission for future treat-
ment during relapse.
Cultured LAK cells consist of a mixture of activated T
cells and natural killer (NK) cells (Ortaldo et al., 1986), and
the latter population has been shown to mediate most LAK
activity (Herberman et al., 1987; Ortaldo et al., 1986; Phillips
& Lanier, 1986). In our previous studies in patients with
leukaemia, only a mean of 9% of IL-2-cultured peripheral
blood mononuclear cells (PBMNC) had the CD3-CD56+
(NK) phenotype (Adler et al., 1988; Adler et al., 1989).
Recently, enrichment of human PBMNC in CD3-CD56+
antitumour effector cells has been achieved by adherence to
plastic and subsequent culture in IL-2 of adherent lympho-
kine-activated killer (A-LAK) cells (Melder et al., 1988;
Rabinowich et al., 1991; Sedlmayr et al., 1991), which display
higher antitumour cytotoxicity in vitro and better in vivo
antimetastatic (Schwarz et al., 1989) and antitumour (Sacchi
et al., 1991) activities than conventional LAK cells. As only a
minor fraction of NK cells adhere to plastic after 24 h of
IL-2 activation, good expansion of A-LAK cells in culture is
necessary to obtain sufficient cells for therapy. In contrast to
A-LAK cells obtained from normal individuals, those from
cancer patients with metastatic disease frequently fail to
expand in culture (Sedlmayr et al., 1991; Whiteside et al.,
1990).
The purpose of this study was to define conditions for
optimal expansion of A-LAK cells in patients with acute
myelogenous leukaemia (AML). By adding irradiated feeder
cells to cultures of A-LAK cells, a significant and selective
enhancement in the proliferation of NK cells can be ob-
tained. This approach may improve the feasibility of AIT
with IL-2 activated NK cells in patients with acute nonlym-
phoblastic leukaemia and possibly other haematologic neo-
plasms.
Patients and methods
Patients andnormal controls
Cryopreserved peripheral blood mononuclear cells (PBMNC)
from ten patients with acute myelogenous leukaemia were
used. All patients were seen by the Hematology Service at the
University of Pittsburgh Medical Center. Four patients were
in remission between 51 and 172 days since their last therapy
with daunoblastin and cytosine arabinoside. Six patients were
untreated, and leukaemic blasts were not demonstrated in
their peripheral blood at presentation.
PBMNC were also obtained from normal volunteers.
PBMNC were separated on Ficoll-Hypaque gradients, wash-
ed, counted, and cryopreserved using a Cryomed (Mt. Cle-
mens, MI).
Bone marrows (BM) were obtained from normal volun-
teers using heparin as anti-coagulant. BM cells were separ-
ated on Ficoll-Hypaque density gradients, washed twice in
RPMI 1640, and either cryopreserved or used immediately as
targets in 4 h 51Cr release assays.
Culture medium
For generation of A-LAK cells and preparation of PBL
feeder cells, RPMI 1640 medium supplemented with 10%
(v/v) pooled heat-inactivated human AB-serum (HABS),
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2 mM glutamine, 50 U ml-' penicillin, 50jigml1 streptomy-
cin and 25 mM Hepes buffer (all from Gibco, Grand Island,
NY) was used. The medium is referred to as tissue culture
medium (TCM).
Generation ofA-LAK cells
Cryopreserved PBMNC were rapidly thawed, washed 3 x,
and resuspended in TCM. Whenever cell numbers were
sufficiently high, monocytes were depleted by incubation for
40 min in medium containing phenylalanine-methyl ester
(PME, 1 mg ml-' 107 cells, DuPont de Nemours, Glenolden,
PA.). After three washes, the cells were placed in T25 poly-
styrene culture flasks (Corning, NY) at a concentration of up
to 5 x 106 cells ml-' in a total volume of 5 ml of TCM to
which IL-2 had been added (1,000 Cetus units ml-' or
6,000 IU ml-1; Cetus, Emeryville, CA). The flasks were incu-
bated lying flat at 37°C in humidified atmosphere of 5% CO2
in air. After 24 h, nonadherent cells were removed, and the
flasks were washed with prewarmed (37°C) RPMI medium
containing 2% HABS and 25 mM Hepes-buffer. The plastic-
adherent cells were counted using an inverted microscope and
the autologous conditioned medium was added back to the
flasks for culture of adherent cells.
Preparation ofPBL-feeder-cells
PBL obtained from normal donors were incubated with
10 yg ml-' of concanavalin A (Con A; Sigma, St. Louis) and
50 U ml1' of IL-2 for 3 d at 37°C in TCM. Cells were then
irradiated at 5000 R and added to A-LAK-cultures on day 1
at a concentration of 106 cells ml-' as feeder cells.
Cell lines
The Epstein Barr virus (EBV)-transformed lymphoblastoid
cell lines, DEM and DBB (obtained from the XI Interna-
tional Histocompatibility workshop), the human myeloid
leukaemia cell line, K562, and the human Burkitt lymphoma-
derived cell line, Daudi, were maintained in culture in RPMI-
1640 medium supplemented with 10% (v/v) heat-inactivated
foetal calf serum (FCS, GIBCO). The cell lines were subcul-
tured as needed, and cells in the log phase of growth were
used as feeders and for cytotoxicity assays. To be used as
feeders, EBV-LCL were irradiated at 25,OOOR and added at a
concentration of 2 x 105 cells ml -to A-LAK cell cultures on
day 1. All cell lines were mycoplasma free, as determined by
DNA hybridisation using Gen-Probe kit (San Diego, CA).
Assessment ofproliferation
Fold expansion of A-LAK cells was determined by cell
counts performed in the presence of trypan blue. To calculate
fold expansion, the total cell number in culture was divided
by the number of adherent cells observed after the first 24 h
of rIL2 activation.
Cytotoxicity assay
5'Cr-release cytotoxicity assays were performed as described
by us earlier (40). NK-sensitive (K562), NK-resistant (Daudi)
cell lines as well as cryopreserved leukaemic blasts or cryo-
preserved bone marrow cells from healthy donors served as
targets to measure cytolytic activity of A-LAK-cells. Target
cells (1 x 106) were labelled with 150gsCi sodium 5'Cr-chro-
mate (NEN, Boston, MA; specific activity = 5 Ci mol-') for
1 h at 37°C, washed three times in RPMI 1640 containing
10% (v/v) FCS, and dispensed into wells of 96-well U-
bottom plates (5 x 103/well). Effector to target (E:T) cell
ratios ranged from 6:1 to 0.375:1 or from 50:1 to 6:1 for
AML blasts. Triplicate wells were set up for each E:T ratio
tested. After centrifugation of the plates, the cells were
incubated for 4h at 37°C in 5% CO2 in air. Supernatants
were harvested using a Skatron Harvester System. Control
wells for spontaneous 5'Cr release contained medium only.
Maximum release was determined by the addition of 5%
Triton-X-100 to targets. The percentage specific lysis was
determined according to the formula:
mean cpm experimental release - mean cpm spont. release
mean cpm maximal release - mean cpm spont. release
x 100
Lytic activity was calculated according to the equation of
Pross et al. (Pross et al., 1981). One lytic unit (LU) was
defined as the number of effector cells required to lyse 20%
of 5 x 103 target cells in a 4 h cytotoxicity assay and cal-
culated per 107 effector cells.
Spontaneous release of 5'Cr was less than 20% of the total
chromium incorporation for fresh cryopreserved leukaemia
cells and less than 10% for cultured tumour cell targets.
Total lytic activity of a culture was calculated as LU/107
cells multiplied by the cell count.
Flow cytometry
NK and T cells were quantified by two-colour flow cyto-
metry performed on a FACScan with the following mono-
clonal antibodies: Leu4 (anti-CD3), Leul9 (anti-CD56), and
Leulla (anti-CD16), which were purchased from Becton
Dickinson (Mountain View, CA) as were Leul2 (anti-CD20)
and LeuM3 (anti-CD14), which were used to exclude the
presence of B cells or monocytes, respectively. Unlabelled
UCHL1 (anti-CD45RO) was obtained from DAKO (Caran-
teria, CA), while 4B4 (anti-CD29) and 2H4 (anti-CD45RA
were purchased from Coulter (Hialeah, FL) and used
in indirect immunofluorescence together with anti-mouse
IgG F(ab')2-FITC (Tago, Burlingame, CA). Titrations were
performed with normal PBMNC to determine the optimal
dilutions of all reagents used for flow cytometry.
Cells (0.5 x 106) were pelleted, washed, and resuspended in
0.2 ml PBS + 0.1% (w/v) sodium azide. Monoclonal anti-
body (5 gil) was added to each tube, and the samples were
incubated at 4°C for 15 min. The stained cells were washed
twice with PBS/sodium azide buffer and resuspended in 2%
(v/v) paraformaldehyde. Controls were unstained cells in the
PBS/sodium azide buffer, and isotype controls (IgG, and
IgG2a) were used to set markers. Also, all cell suspensions
were stained with antibody to the pan-leukocyte antigen,
anti-HLe-l (Becton Dickinson).
Statistical analysis
Significance of differences in the fold expansion, cytotoxicity
and percentages of cells positive for different surface markers
were calculated using Mann-Whitney's U-test. In order to
determine the significance of these differences between paral-
lel cultures in the same individuals, Wilcoxon's signed rank
test was employed. Fisher's exact test was used for com-
parisons of cultures grown with and without feeders.
Results
Proliferation ofA-LAK cell cultures
Since A-LAK cultures were started from IL2-activated plas-
tic-adherent NK cells, it was important to determine the
proportion of such plastic-adherent cells in cultures of pa-
tients' PBMNC. The mean percentage (± s.e.m.) of cells
adhering to plastic, which were obtained by culture of
monocyte-depleted PBMNC for 1 day in the presence of IL2,
in all patients with AML participating in the study was
1.1 ± 0.4% (range 0.02-3.4%). However, a significant
difference (P<0.03) in the percentage of cells adhering to
plastic was observed between the untreated patients (mean
0.5 ± 0.2 (s.e.m.); range 0.02-1.2) and those in remission
(mean 2.2 ± 0.6 (s.e.m.); range 0.6-3.4). The efficiency of
adherence to plastic of lymphocytes, obtained from patients
in remission was comparable to that of normal donors under
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A-LAK cells, which were derived from cryopreserved PBL
of patients with AML in a conventional way, i.e., without
feeder cells, had a median expansion of 2 fold (n = 9, range
1-14) after 14 days in cultures (Figure 1). Cultures growing
in the presence of ConA-prestimulated and irradiated allo-
geneic PBL proliferated significantly better (P<0.001), with
a median fold expansion of 290 (n = 8, range 14-3,778).
A-LAK cells cultured in the presence of irradiated LCL as
feeders also grew significantly better (P<0.001) than parallel
cultures without feeders (median fold expansion = 291, n = 9,
range 25-2280).
For comparison, A-LAK cultures were also established
from cryopreserved PBL of normal volunteers in the presence
or absence of feeder cells. As shown in Figure 1, these
normal A-LAK cells had a median fold expansion of
10 without feeders (n = 26, range 1.2-304) compared to
129 fold with ConA-PBL feeders (n = 15, range 7-5477,
P<0.002) and 588 fold with LCL (n = 12, range 200-7200,
P<0.002). The data indicated that although A-LAK cells
generated from cryopreserved PBL of patients with AML
proliferated less well than normal A-LAK in the absence of
feeder cells (P<0.05), addition of the latter allowed for
better A-LAK proliferation in culture. Indeed, A-LAK cells
from all AML patients studied had > 10-fold expansion in
the presence of feeder cells. This proliferation was com-
parable to that of A-LAK cells from normal volunteers in
the presence of ConA-stimulated PBL or LCL as feeder cells.
Phenotype ofA-LAK cell cultures in patients with AML
Since A-LAK cells which express the CD3-CD56+ (NK)
phenotype mediate the antitumour cytotoxicity (Lotzova et
al., 1987; Nagler et al., 1989), our objective was to obtain
cultures highly enriched in CD3-CD56+ cells from patients
with AML. Indeed, in our hands, good enrichment in cells
with CD3-CD56+ phenotype occurred in most A-LAK cul-
tures established from PBMNC of patients as well as normal
individuals, especially, when these cultures contained feeder
cells (Figure 2). Cultures expanded from PBMNC of AML
patients in the presence of ConA-activated PBL or
LCL as feeder cells contained comparable percentages of
CD3-CD56+ cells (medians of 65% and 82%, respectively).
In A-LAK cultures generated from cryopreserved normal
PBMNC the enrichment in CD3-CD56+ cells in the presence
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Figure 1 Growth of A-LAK cell cultures established from
PBMNC of AML patients and normal individuals. A-LAK cells
were cultured for 14 days without feeder cells, with ConA-
stimulated PBL, or with LCL. The bars indicate medians. The
asterisks indicate significant differences (P<0.002) in comparison
to A-LAK cells cultured without feeder cells.
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Figure 2 Percentages of cells expressing the NK-cell phenotype
(CD3-CD56+) in A-LAK cell cultures established from PBMNC
of patients or normal individuals and grown with or without
feeder cells. The phenotypic markers were determined by two-
colour flow cytometry in A-LAK cultures on day 14 of growth.
The bars indicate medians. The asterisk indicates a significant
difference (P<0.01 for ConA-PBL; P<0.001 for LCL) in com-
parison to A-LAK cells cultured without feeder cells.
of ConA-stimulated PBL (median of 84%) and LCL (median
of 89%) was significantly different from A-LAK expanded
without feeders (median of 62%) (P<0.01 for ConA-PBL;
P<0.002 for LCL feeders). In general, the presence of feeder
cells, especially LCL, allowed for a more consistent enrich-
ment in CD3-CD56+ cells in A-LAK cultures from normal
as well as patients' PBMNC.
In all A-LAK cultures, cells other than CD3-CD56+ were
T cells (CD3+CD56+ or CD3+CD56-, see Table I). Mono-
cytes were consistently below 2%. As has been shown before
for IL2-activated NK cells, a high proportion ofA-LAK cells
was negative for the CD16 antigen (Nagler et al., 1989).
Also, A-LAK cells were CD45RO-, CD45RA- and CD29+
(data not shown).
Cytotoxicity ofA-LAK cell cultures in patients with AML
A-LAK cell cultures generated from AML patients in the
presence or absence of feeder cells generally displayed high
levels of cytotoxicity against NK-sensitive cell line K562 as
well as against NK-resistant Daudi targets (Figure 3), with
no significant difference on a per cell basis between A-LAK
cell cultures grown with or without feeder cells. There was
also no statistically significant difference between the levels of
antitumour cytotoxicity between normal and patient A-LAK
cells grown in the presence of feeder cells (Figure 3).
Cytotoxicity against autologous leukaemic blasts was also
determined in those cases, where autologous frozen bone
marrow cells collected at the time of the diagnosis were
available (Figure 4a). In one out of two cases, there was
considerable cytotoxicity against autologous blasts (1,379
LU). Interestingly, these effectors failed to lyse three allo-
geneic AML-blasts (data not shown). In the second case, far
less autologous cytotoxicity was found (11 LU). Cytotoxicity
against cryopreserved allogeneic AML blasts were also meas-
ured in several other cases (Figure 4b). In general, cytotox-
icity against allogeneic blasts was low, with a median of 40
LU and range of 19-1,768.
In 15 cases, A-LAK cells were tested for cytotoxicity
against normal allogeneic bone marrow cells and found to be
able to lyse these normal targets (median 504, range 10-2715
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Table I Phenotypic characteristics of A-LAK cells cocultured with LCL or allogeneic
mitogen-activated PBL as feedersa
% Positive cells
Donors of Feeder CD3- CD,16- CDJ6+ CD16+ CD3+ CD3+
A-LAK cells cells CD56+ CD56+ CD56+ CD56- CD56- CD56+
AMLpatients None 51 ± 12 47 13 16± 1 2± 1 35± 9 12± 3
(n = 7)
AML patients ConA-PBL 62± 9 48 8 25 1 2± 1 23 9 8± 2
(n = 7)
AML patients LCL 77 ± 5 69± 5 13 6 1 0 12 5 5 10
(n = 8)
Normal None 53 ± 9 ND ND ND 18 6 14± 4
(n= 14)
Normal ConA-PBL 80± 7b 55 15 43 15 3 2 7 5 5± 2
(n= 14)
Normal LCL 90± 2c 37 11 60 11 3 2 3 1 7± 2
(n= 11)
aTwo-colour flow cytometry was used to determine proportions of different lymphocyte
subpopulations in A-LAK cells cocultured for 14 days with prestimulated and irradiated allogeneic
PBL or LCL. Data are means ± s.e.m. bSignificantly different from A-LAK cells ofnormal controls
grown without feeder cells (P<0.01). cSignificantly different from A-LAK cells ofnormal controls
grown without feeder cells (P<0.001).
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Figure 3 Antitumour cytotoxicity of A-LAK cells in cultures
established from patients with AML or normal volunteers. A-
LAK cultures grown in the presence or absence of ConA-PBL or
LCL as feeder cells for 14 days were tested in 4h 5'Cr-release
assays against K562 and Daudi targets. The data are means
± s.e.m.
LU/107 cells, see Figure 5). Nevertheless, the susceptibility of
normal BM cells to lysis by A-LAK cells was 10 folds lower
than that of Daudi (median 5240, range 2271-27661 LU/107
cells) and 22 folds lower than that of K562 (median 11350,
range 5455-52885).
We also compared total lytic units (TLU) ofcytotoxicity in
cultures grown from patients' PBL with or without ConA-
activated PBL or LCL as feeder cells (Figure 6). Total lytic
activity against both K562 and Daudi in A-LAK cell cultures
grown with feeder cells was significantly greater than that in
paired cultures grown without feeders (P<0.02 for ConA-
PBL; P<0.005 for LCL).
Quality ofA-LAK cells generatedfrom patients with AML
Our results indicated that in spite of overall improvement in
growth of A-LAK cells in the presence of feeders, some
heterogeneity existed among patients in regard to the aug-
menting effects of feeder cells on expansion, phenotype and
Pt. 1 Pt.2 Pt.3 Pt.4 Pt.5 Pt.6
Figure 4 Cytotoxicity of A-LAK cells obtained from AML
patients against autologous fresh leukaemic blasts a, and allo-
geneic leukaemic blasts b, in comparison to cytotoxicity against
K562 or Daudi targets. Cytotoxicity was tested in 4 h 5'Cr-release
assays.
cytotoxicity of cultured effector cells. As a practical para-
meter to discriminate between patients with good and im-
paired ability to generate A-LAK cells in vitro, we arbitrarily
defined 'good' A-LAK generation as: expansion > 100 fold
with CD3-CD56+ cells > 50% and 'borderline' cultures as:
expansion > 50 fold with CD3-CD56+ cells > 80%. Among
eight A-LAK cultures grown from patients' PBMNC in the
presence of ConA-stimulated feeders, four were considered
'good' and one 'borderline' (success rate of 62%; Table II). A
similar success rate was obtained in presence of LCL feeders,
where five 'good' out of eight A-LAK cultures were gener-
ated. None of the nine cultures grown without feeder cells
met the above criteria. Thus, the addition of feeder cells
resulted in a significant improvement of A-LAK generation
in patients with AML (P<0.02 for both PBL and LCL
feeders) from cryopreserved PBMNC. It may be important to
note that 'good' in vitro responses occurred both among
patients treated and not previously treated with
chemotherapy (Table II).
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Figure 5 Cytotoxicity of A-LAK cells obtained from PBMNC
of normal donors against normal bone marrow (BM) cells in
comparison to cytotoxicity against K562 or Daudi targets. Cyto-
toxicity was measured in 4 h 5'Cr release assays. The bars indi-
cate medians. The asterisk indicates a significant difference
(P<0.0001) between levels of cytotoxicity against tumour targets
vs that against normal BM.
Discussion
NK cells appear to play an important role in defence against
cancer, including leukaemia. It has been observed that NK
activity in patients with preleukaemic disorders or with
leukaemia in acute stage or in relapse is often decreased
(Lotzova et al., 1986; Pizzolo et al., 1988; Whiteside &
Herberman, 1989). In contrast, NK activity tends to return
to normal in remission (Lotzova et al., 1986; Pizzolo et al.,
1988). These observations suggested that there exists a cor-
relation between NK activity and the disease activity in acute
leukaemia. Also, NK cells from patients with leukaemia
(acute and chronic, lymphocytic and myelogenous) have been
shown to be impaired in their ability to bind to and lyse
tumour cells, in their recycling capacity, and in production of
NK cytotoxic factor (Lotzova, 1984; Lotzova et al., 1986).
These defects can be, at least in part, reversed in vitro by the
addition of IL-2 (Lotzova et al., 1987). On the basis of such
in vitro observations, it has been suggested that AIT with
IL-2 activated NK cells may be effective in control of lym-
phoproliferative disorders. A-LAK cells could be used for
AIT of human leukaemias, if available in numbers sufficient
for therapy.
Our data demonstrate the feasibility of generating large
quantities of highly cytotoxic A-LAK cells from cryopre-
served peripheral blood mononuclear cells (PBMNC) or
patients with untreated as well as remitted acute myelo-
genous leukaemia (AML). In this disease, A-LAK generation
in the presence of IL-2 and conditioned medium only, as
originally described by Melder et al. (Melder et al., 1988), is
generally poor. In order to improve and optimise this techni-
que for cells of patients with AML, ConA-prestimulated
allogeneic PBL or EBV-transformed allogeneic LCL were
Figure 6 Total lytic units of antitumour activity in A-LAK
cultures from AML patients. A-LAK cells were cultured in the
presence or absence of feeder cells for 14 days and then tested for
cytotoxicity against K562 and Daudi targets. The bars are
medians. The asterisks indicate significant differences (P<0.02
for ConA-PBL; P<0.005 for LCL) in comparison to A-LAK
cells cultured without feeder cells.
Table II Quality of A-LAK cultures from patients with ANLL
Generation ofA-LAK cells'
Stage No ConA-PBL LCL
Patients Diagnosis ofdisease feeders feeders feeders
P.T. ANLL-M4 Untreated - + +
M.M. ANLL-M4 Untreated nd + +
M.L. ANLL-M3 Untreated - +
K.F. ANLL-M4 Untreated - nd
E.C. ANLL-M4 Untreated - + nd
D.P. ANLL Untreated - - nd
T.K. ANLL-M3 Remission - nd +
M.S. ANLL-M3 Remission -
G.D. ANLL-M2 Remission - - +
E.E. ABKK-M2 Remission - + +
AML 0/9 5/8b 5/8b
patients (62%) (62%)
Normal 3/12 11/13 11/1lC
controls (25%) (84%) (100%)
"'Good' (+) A-LAK cell cultures were defined as those with
expansion > 100 fold and CD3-CD56+ >50%; 'Borderline' (±)
A-LAK cultures had expansion > 50 fold and CD3-CD56+ > 80%;
'negative' (-) cultures failed to generate A-LAK cells underconditions
defined in Materials and methods. bThe frequency .of 'good' or
'borderline' cultures was significantly increased compared to A-LAK
witout feeder cells (P<0.01). 'The frequency of 'good' or 'borderline'
cultures was significantly greater than in AML patients (P<0.005).
added as feeder cells to patient PBMNC cultures in the
presence of IL-2. This approach has been shown by us
recently to improve A-LAK generation in both normal indi-
viduals (Rabinowich et al., 1991) and patients with solid
cancers (Sedlmayr et al., 1991). The addition of feeder cells
to cryopreserved patient PBMNC increased in vitro prolifera-
tion of these cells to levels which were significantly greater
than those in paired cultures grown without feeders and as
good as those of normal PBMNC grown under comparable
conditions. In addition to increasing proliferation, the pre-
sence of feeder cells also seemed to improve consistency of
obtaining cultures highly enriched in CD3-CD56+ cells. It is
unclear by what mechanism feeder cells augment A-LAK cell
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proliferation. We hypothesise that they provide growth fac-
tors necessary for successful expansion of enriched NK cells
in vitro.
A number of investigations have demonstrated that LAK
activity can be generated from PBMNC of leukaemic pa-
tients in remission (Adler et al., 1988; Adler et al., 1989;
Findley et al., 1988; Tahara et al., 1988; Teichmann et al.,
1989), and, on the basis of these preclinical studies, immuno-
therapy with rIL2 is being used in patients with acute
leukaemia (Foa et al., 1990a; Foa et al., 1990c; Gottlieb et
al., 1989). The main intent of such immunotherapy is to
eliminate minimal residual disease through in vivo activation
of LAK cell precursors (Gottlieb et al., 1989). More recent
studies seem to indicate, however, that autologous LAK cells
might not be as effective for this purpose as originally
expected, because LAK activity, as well as NK activitiy, is
impaired in leukaemia patients at presentation (Foa et al.,
1990b). It appears that both defective lytic activity of the
effectors and resistance of leukaemic blasts to lysis by these
effectors may be responsible for this impairment (Foa et al.,
1991). Indeed, our study illustrates that patients with acute
nonlymphocytic leukaemia (ANLL) at presentation or in
remission are not able to generate IL-2 activated NK effector
cells unless special in vitro conditions are provided. This
might indicate that the impairment in effector cell generation
and/or function is reversible when NK cells are separated
from putative suppressor cells or factors and provided with
necessary growth factors in vitro.
Successful generation of A-LAK cells from patients in the
chronic phase of chronic myelogenous leukaemia (CML) has
been recently reported (Verfaillie et al., 1989). As compared
to unseparated LAK cells from the same patients, these
A-LAK cells demonstrated superior antitumour cytotoxicity
in vitro. Importantly, these A-LAK cells were Philadelphia
chromosome-negative and did not show the ber gene re-
arrangement in contrast to the leukaemic cells in the same
patients. In a more recent study, Verfaillie et al. (Verfaillie et
al., 1990) reported that proliferation of A-LAK cells from
patients with CML was significantly increased compared to
A-LAK cells from normal volunteers, but the ability to
proliferate in vitro declined in parallel with the progression of
the disease. When added to our observations, these data
strongly suggest that it is feasible to generate sufficient
numbers of A-LAK cells for AIT in patients with leukaemias
especially in early disease and in remission.
Considerable information has been acquired regarding lysis
of leukaemic blasts by LAK cells. Most leukaemic cell lines
have been shown to be susceptible in vitro to lysis by LAK
cells. However, killing of these cell lines does not appear
to correlate with cytotoxicity against autologous leukaemic
blasts (Foa et al., 1991). While fresh leukaemic blasts are
generally sensitive to LAK cell lysis, most are resistant to
unstimulated NK cells (Adler et al., 1988; Adler et al., 1989;
Fierro et al., 1988; Findley et al., 1988; Lotzova et al., 1987;
Oshimi et al., 1986; Panayotides et al., 1988; Tahara et al.,
1988; Foa et al., 1991). Also, inherent resistance of leukaemic
blasts to LAK-mediated lysis has been observed in acute
leukaemic patients with active disease (Foa et al., 1991). To a
limited extent, it was possible in this study to check
effectiveness of patients' A-LAK cells against fresh
cryopreserved allogeneic AML blasts. These leukaemic
targets were variably sensitive to lysis by A-LAK cells, with
some fresh targets showing considerable sensitivity. It has
been suggested that the presence of LAK activity against
autologous blasts may be a useful marker of disease (Foa et
al., 1991). In two cases, we tested fresh AML blasts for lysis
by autologous A-LAK cells, and demonstrated good levels of
activity in one case. Overall, autologous killing by A-LAK
cells may be a more useful measure of antitumour immunity
than lysis of leukaemic cell lines. Although the addition of
feeder cells to A-LAK cells did not significantly augment
their cytotoxicity against K562, and Daudi (on a per cell
basis), due to increased proliferation of A-LAK cells in the
presence of feeder cells, TLU of anti-K562 and anti-Daudi
activity were significantly increased. Further experiments
need to be performed to investigate the possibility that feeder
cells might alos improve in vitro generation of A-LAK cells
with high levels of cytotoxicity against allogeneic and
autologous leukaemic blasts.
LAK cells have been shown to have little cytotoxicity
against normal bone marrow cells (Van den Brink et al.,
1989; Van den Brink et al., 1990). In competitive inhibition
assays, normal bone marrow cells failed to compete with
LAK effectors for killing of hematopoietic tumour cell lines,
K562 and HL60, or fresh-frozen AML blasts (Trinchieri et
al., 1987). Furthermore, LAK cells had no inhibitory effect
on hematopoietic growth in colony forming assays (Van den
Brink et al., 1989). Nevertheless, a concern that IL-2 acti-
vated effectors may damage normal bone marrow cells exists,
because of evidence that NK cells might suppress hemato-
poietic stem cell function in vitro (Trinchieri et al., 1987). In
particular, inhibition of clonogenic growth of human AML
stem cells by LAK cells has been reported (Lista et al., 1989).
As A-LAK cells derived from PBMNC of normal volunteers
have significantly higher antitumour cytolytic activity on a
per cell basis than LAK cells, the possibility exists that
A-LAK cells may cause adverse effects on normal hemato-
poietic progenitor cells. Our observation that, in 15 cases,
normal bone marrow cells were lysed by A-LAK cells
appears to be important and deserves further studies. How-
ever, the highly significant difference observed in sensitivity
to the cytolytic activity of A-LAK cells between tumour cell
lines (K562 or Daudi) and normal bone marrow cells suggest
that A-LAK preferentially kill tumour cells. This difference
in susceptibility to lysis by A-LAK cells can perhaps be used
to advantage in designing a therapeutic protocol that would
optimise the ability of A-LAK cells to kill leukaemic cells
and yet diminish damage to normal bone marrow elements.
If, however, A-LAK cells prove to be highly toxic to
hematopoietic progenitor cells, the rationale for AIT with
A-LAK cells in patients with leukaemia may have to be
reevaluated.
In summary, we have demonstrated that generation of
highly homogeneous populations of IL2-activated NK cells
from cryopreserved PBMNC is feasible in patients with
AML, especially since use of irradiated, allogeneic, ConA-
activated feeder cells significantly enhances proliferation of
A-LAK cells, increases consistency of obtaining cultures
highly enriched in CD3-CD56+ effectors and augments total
anti-tumour activity.
P. Sedlmayr is a recipient of a fellowship grant from the Max Kade -
Foundation.
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